Navin Jacob
Stock Analyst at UBS
(2.82)
# 1,830
Out of 4,711 analysts
25
Total ratings
64.29%
Success rate
18.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Navin Jacob
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Neutral | $195 → $200 | $175.58 | +13.91% | 11 | Oct 31, 2024 | |
| LLY Eli Lilly | Upgrades: Buy | $363 | $767.76 | -52.72% | 8 | Sep 22, 2022 | |
| RPRX Royalty Pharma | Upgrades: Buy | $51 | $24.92 | +104.65% | 1 | Nov 9, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $92.57 | - | 1 | Apr 27, 2020 | |
| MRK Merck & Co. | Maintains: Buy | $96 → $92 | $98.05 | -6.17% | 4 | Apr 13, 2020 |
AbbVie
Oct 31, 2024
Maintains: Neutral
Price Target: $195 → $200
Current: $175.58
Upside: +13.91%
Eli Lilly
Sep 22, 2022
Upgrades: Buy
Price Target: $363
Current: $767.76
Upside: -52.72%
Royalty Pharma
Nov 9, 2020
Upgrades: Buy
Price Target: $51
Current: $24.92
Upside: +104.65%
Gilead Sciences
Apr 27, 2020
Downgrades: Neutral
Price Target: n/a
Current: $92.57
Upside: -
Merck & Co.
Apr 13, 2020
Maintains: Buy
Price Target: $96 → $92
Current: $98.05
Upside: -6.17%